JP2004521117A - メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン - Google Patents
メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン Download PDFInfo
- Publication number
- JP2004521117A JP2004521117A JP2002559409A JP2002559409A JP2004521117A JP 2004521117 A JP2004521117 A JP 2004521117A JP 2002559409 A JP2002559409 A JP 2002559409A JP 2002559409 A JP2002559409 A JP 2002559409A JP 2004521117 A JP2004521117 A JP 2004521117A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- formula
- hydrogen
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C=*CC(C1)[*+]Cc2c1cccc2 Chemical compound C=*CC(C1)[*+]Cc2c1cccc2 0.000 description 14
- XSSWFYSBSGAYOD-UHFFFAOYSA-N CC(C)(C)OC(N1C(CC(O)=O)c2ccccc2C1)=O Chemical compound CC(C)(C)OC(N1C(CC(O)=O)c2ccccc2C1)=O XSSWFYSBSGAYOD-UHFFFAOYSA-N 0.000 description 2
- KZGANJFEUHORED-UHFFFAOYSA-N C=[Br]c1c(C=C(CC2)N3CCOCC3)c2ccc1 Chemical compound C=[Br]c1c(C=C(CC2)N3CCOCC3)c2ccc1 KZGANJFEUHORED-UHFFFAOYSA-N 0.000 description 1
- ZTXJCCMGHPXAGQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1c(cncc2)c2ccc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1c(cncc2)c2ccc1)=O ZTXJCCMGHPXAGQ-UHFFFAOYSA-N 0.000 description 1
- ZAWPAGYWUKXQNK-VQCQRNETSA-N CC(C)(C)OC(N1C(CC(N[C@H](Cc(cc2)ccc2Cl)C(OC)=O)=O)c2ccccc2C1)=O Chemical compound CC(C)(C)OC(N1C(CC(N[C@H](Cc(cc2)ccc2Cl)C(OC)=O)=O)c2ccccc2C1)=O ZAWPAGYWUKXQNK-VQCQRNETSA-N 0.000 description 1
- WCSOQNUPONWLSG-UHFFFAOYSA-N CCOC(C(C1)NC(C)(C)c(cc2)c1cc2OC)=O Chemical compound CCOC(C(C1)NC(C)(C)c(cc2)c1cc2OC)=O WCSOQNUPONWLSG-UHFFFAOYSA-N 0.000 description 1
- RMKUIMTVLKSVEX-UHFFFAOYSA-N CCOC(C(Cc1c2)NC(C)(C)c1ccc2O)=O Chemical compound CCOC(C(Cc1c2)NC(C)(C)c1ccc2O)=O RMKUIMTVLKSVEX-UHFFFAOYSA-N 0.000 description 1
- YXOVIGZJPGLNGM-UHFFFAOYSA-N Cc1cccc2c1CCCC2 Chemical compound Cc1cccc2c1CCCC2 YXOVIGZJPGLNGM-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N OS(C(F)(F)F)(=O)=O Chemical compound OS(C(F)(F)F)(=O)=O ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26359501P | 2001-01-23 | 2001-01-23 | |
| PCT/US2002/000516 WO2002059107A1 (en) | 2001-01-23 | 2002-01-23 | Substituted piperidines/piperazines as melanocortin receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521117A true JP2004521117A (ja) | 2004-07-15 |
| JP2004521117A5 JP2004521117A5 (https=) | 2005-12-22 |
Family
ID=23002443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559409A Pending JP2004521117A (ja) | 2001-01-23 | 2002-01-23 | メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7157463B2 (https=) |
| EP (1) | EP1368339A1 (https=) |
| JP (1) | JP2004521117A (https=) |
| CA (1) | CA2433025A1 (https=) |
| WO (1) | WO2002059107A1 (https=) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2432988A1 (en) | 2001-01-23 | 2002-08-01 | Cristina Garcia-Paredes | Melanocortin receptor agonists |
| ES2247298T3 (es) | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | Derivados de piperazina y piperidina como agonistas del receptor de melanocortina. |
| CA2438272A1 (en) | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| WO2003061660A1 (en) | 2002-01-23 | 2003-07-31 | Eli Lilly And Company | Melanocortin receptor agonists |
| US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004024720A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| WO2004048345A2 (en) * | 2002-11-22 | 2004-06-10 | Novo Nordisk A/S | 2,5-diketopiperazines for the treatment of obesity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| KR100751604B1 (ko) | 2003-03-03 | 2007-08-22 | 에프. 호프만-라 로슈 아게 | 5-ｈｔ6 조절자로서 사용되는 2,5- 및 2,6-치환된테트라하이드로아이소퀴놀린 |
| WO2004078717A1 (en) | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
| EP1468999A1 (en) * | 2003-03-20 | 2004-10-20 | MyoContract Ltd. | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| CN1764458A (zh) | 2003-03-26 | 2006-04-26 | 麦克公司 | 作为黑皮质素－4受体激动剂的双环哌啶衍生物 |
| ATE547404T1 (de) | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
| US20050119252A1 (en) * | 2003-10-22 | 2005-06-02 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| EP1685102A4 (en) * | 2003-11-12 | 2008-08-20 | Lg Life Sciences Ltd | melanocortin |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
| JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
| WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
| WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
| EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| AU2006304305B2 (en) | 2005-10-18 | 2010-04-01 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| JP2009512715A (ja) | 2005-10-21 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ |
| EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
| ES2381205T3 (es) | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | ALKYLAMINOPYRIDINDERIVATE |
| WO2009119726A1 (ja) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Ｍｓｄ株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
| US8227628B2 (en) | 2008-07-09 | 2012-07-24 | Northwestern University | Method of synthesizing acetonide-protected catechol-containing compounds and intermediates produced therein |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES |
| CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| JP6330040B2 (ja) | 2013-07-22 | 2018-05-23 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−（ピペラジン−１−イル）−２−（［１，２，４］トリアゾール−１−イル）−エタノン誘導体 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| AR099789A1 (es) * | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| PL3245203T3 (pl) | 2015-01-15 | 2019-05-31 | Idorsia Pharmaceuticals Ltd | Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3 |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| AU2019280689B2 (en) * | 2018-06-05 | 2024-09-05 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof |
| AR117122A1 (es) | 2018-11-20 | 2021-07-14 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
| PL4019485T3 (pl) | 2019-08-23 | 2024-10-21 | Mochida Pharmaceutical Co., Ltd. | Sposób wytwarzania pochodnych heterocyklidenoacetamidu |
| WO2021039023A1 (ja) * | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
| PE20240124A1 (es) * | 2020-10-29 | 2024-01-22 | Lg Chemical Ltd | Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
| IL302427A (en) * | 2020-10-29 | 2023-06-01 | Lg Chemical Ltd | A crystalline structure of a melanocortin receptor agonist and a method for its preparation |
| JP2023548161A (ja) * | 2020-10-29 | 2023-11-15 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉｖおよびその製造方法 |
| US20230382895A1 (en) * | 2020-10-29 | 2023-11-30 | Lg Chem, Ltd. | Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor |
| AU2021370071B2 (en) * | 2020-10-29 | 2024-01-11 | Lg Chem, Ltd. | Amorphous melanocortin-4 receptor agonist |
| JP2024501828A (ja) * | 2020-12-22 | 2024-01-16 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法 |
| JP2024501829A (ja) * | 2020-12-22 | 2024-01-16 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉｉｉおよびその製造方法 |
| KR20220090450A (ko) * | 2020-12-22 | 2022-06-29 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체의 선택적 항진제로서의 용도 |
| JP2024500966A (ja) * | 2020-12-22 | 2024-01-10 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法 |
| CN116761611A (zh) * | 2021-01-21 | 2023-09-15 | 株式会社Lg化学 | 黑皮质素-4受体激动剂的用途 |
| US20240190856A1 (en) * | 2021-02-26 | 2024-06-13 | Lg Chem, Ltd. | Melanocortin-4 receptor agonist |
| MX2023013044A (es) * | 2021-05-06 | 2023-11-15 | Lg Chemical Ltd | Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma. |
| BR112023022863A2 (pt) * | 2021-05-06 | 2024-01-23 | Lg Chemical Ltd | Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo |
| US20240239769A1 (en) * | 2021-05-07 | 2024-07-18 | Lg Chem, Ltd. | Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same |
| EP4317148A4 (en) * | 2021-05-07 | 2024-09-18 | Lg Chem, Ltd. | MELANOCORTIN RECEPTOR AGONIST COMPOUND SULFATE CRYSTALS AND PROCESS FOR PRODUCTION THEREOF |
| AU2022271120A1 (en) * | 2021-05-07 | 2023-11-09 | Lg Chem, Ltd. | Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013696A1 (en) | 1992-12-11 | 1994-06-23 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| EP1076649A4 (en) | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
| US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| WO1999064002A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| CA2377369A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| JP2003527444A (ja) | 2000-03-23 | 2003-09-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体 |
| WO2001070708A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
| JP2004506687A (ja) | 2000-08-23 | 2004-03-04 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| CA2432988A1 (en) | 2001-01-23 | 2002-08-01 | Cristina Garcia-Paredes | Melanocortin receptor agonists |
| ES2247298T3 (es) | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | Derivados de piperazina y piperidina como agonistas del receptor de melanocortina. |
| CA2438272A1 (en) | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
-
2002
- 2002-01-23 EP EP02701923A patent/EP1368339A1/en not_active Withdrawn
- 2002-01-23 US US10/466,249 patent/US7157463B2/en not_active Expired - Fee Related
- 2002-01-23 CA CA002433025A patent/CA2433025A1/en not_active Abandoned
- 2002-01-23 JP JP2002559409A patent/JP2004521117A/ja active Pending
- 2002-01-23 WO PCT/US2002/000516 patent/WO2002059107A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20040058936A1 (en) | 2004-03-25 |
| EP1368339A1 (en) | 2003-12-10 |
| US7157463B2 (en) | 2007-01-02 |
| WO2002059107A8 (en) | 2003-11-06 |
| WO2002059107A1 (en) | 2002-08-01 |
| CA2433025A1 (en) | 2002-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004521117A (ja) | メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン | |
| EP1370558B1 (en) | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | |
| US7169777B2 (en) | Melanocortin receptor agonists | |
| US7314879B2 (en) | Melanocortin receptor agonists | |
| JP2004524297A5 (https=) | ||
| JP4336196B2 (ja) | メラノコルチン受容体作動薬としての架橋ピペリジン誘導体 | |
| JP4323169B2 (ja) | メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体 | |
| US6350760B1 (en) | Substituted piperidines as melanocortin-4 receptor agonists | |
| AU2002235323A1 (en) | Substituted piperidines/piperazines as melanocortin receptor agonists | |
| AU2002235322A1 (en) | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | |
| AU2002246969A1 (en) | Melanocortin receptor agonists | |
| AU2003202852A1 (en) | Melanocortin receptor agonists | |
| AU2002235324A1 (en) | Melanocortin receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040720 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040720 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080415 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080711 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080718 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080813 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080909 |